Document is current
Any future updates will be listed below
-
Authors
Südmeyer, Martin
Pedrosa, David J.
Siebecker, Frank
Arlt, Carolin
Kopra, Jaakko
Jost, Wolfgang H.
-
Funding
Funding for this research was provided by:
AbbVie Deutschland
- License Information
-
More Information
Article History
Received: 26 October 2024
Accepted: 26 March 2025
First Online: 12 May 2025
Declarations
:
: The study was conducted in accordance with the latest version of the Declaration of Helsinki and was approved by the ethics committee of Landesärztekammer Brandenburg (No. 2021–2188-BO-ff).
: All participating patients gave written informed consent prior to inclusion in the study.
: Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: MS reports receiving consulting fees and lecture fees from Abbott, Boston Scientific, AbbVie, Medtronic, Zambon, Stadapharma, UCB, and Desitin. DJP reports consulting and/or lecturer fees from Bayer, Boston Scientific Corp, Medtronic, AbbVie Inc, Zambon, and Esteve Pharmaceuticals GmbH. FS has served as consultant to AbbVie and received a consultant fee from AbbVie. WHJ is a consultant or speaker for AbbVie, Bial, Britannia, Desitin, Esteve, and Zambon. CA and JK are full-time employees of AbbVie and may own AbbVie stock.
